Alexandros Makriyannis

Company: Center for Drug Discovery, Northeastern University

Job title: Director

Seminars:

Advancing a Neutral Antagonist of the CB1 Receptor in Preclinical Development for Alcohol, Opioid & Cocaine Use Disorders 11:30 am

Looking at how AM6527, a neutral CB1 receptor antagonist, effectively inhibits heroin and cocaine self-administration under progressive-ratio reinforcement schedules in addiction models Discussing behavioural effects and tolerance development in preclinical findings Analyzing safety profile and future directions, comparing to Rimonabant suggests it may offer a safer alternative for treating substance use disordersRead more

day: Conference Day 1

Advancing a Neutral Antagonist of the CB1 Receptor in Preclinical Development for Alcohol, Opioid & Cocaine Use Disorders 11:30 am

Looking at how AM6527, a neutral CB1 receptor antagonist, effectively inhibits heroin and cocaine self-administration under progressive-ratio reinforcement schedules in addiction models Discussing behavioural effects and tolerance development in preclinical findings Analyzing safety profile and future directions, comparing to Rimonabant suggests it may offer a safer alternative for treating substance use disordersRead more

day: Day One AM